ingest
cdrApp
2017-08-15T22:30:54.040Z
d91e81c8-5a8a-4e8a-976c-cad4e396e5ee
modifyDatastreamByValue
RELS-EXT
fedoraAdmin
2017-08-15T22:31:47.067Z
Setting exclusive relation
modifyDatastreamByValue
RELS-EXT
fedoraAdmin
2017-08-15T22:31:56.220Z
Setting exclusive relation
addDatastream
MD_TECHNICAL
fedoraAdmin
2017-08-15T22:31:56.866Z
Adding technical metadata derived by FITS
modifyDatastreamByValue
RELS-EXT
fedoraAdmin
2017-08-15T22:32:14.973Z
Setting exclusive relation
addDatastream
MD_FULL_TEXT
fedoraAdmin
2017-08-15T22:32:24.563Z
Adding full text metadata extracted by Apache Tika
modifyDatastreamByValue
RELS-EXT
fedoraAdmin
2017-08-15T22:32:43.137Z
Setting exclusive relation
modifyDatastreamByValue
RELS-EXT
cdrApp
2017-08-22T13:55:18.899Z
Setting exclusive relation
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2018-01-04T17:18:25.135Z
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2018-01-25T10:16:18.054Z
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2018-01-27T10:29:37.924Z
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2018-02-28T21:11:22.768Z
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2018-03-14T07:18:17.717Z
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2018-05-17T18:45:26.427Z
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2018-07-11T05:45:23.513Z
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2018-07-18T01:59:46.746Z
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2018-08-16T15:11:13.873Z
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2018-09-27T01:40:30.457Z
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2018-10-12T02:12:39.306Z
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2019-03-20T20:31:06.765Z
Dongfen
Yuan
Author
Pharmaceutical Sciences Program
Eshelman School of Pharmacy
DELIVERY OF THERAPEUTIC PROTEINS TO THE BRAIN
Protein therapeutics have tremendous potentials to treat disorders in central nervous system (CNS). However, delivery of therapeutic dose of proteins to the brain is challenging due to the blood-brain barrier (BBB). In Chapter I, I summarize the current strategies applied to enhance the brain delivery of therapeutic proteins, including strategies to open the BBB, penetrate the BBB, or bypass the BBB. The advantages and challenges for each technology are described.
In Chapter II, we explore strategies to improve the brain delivery of leptin for treatment of obesity. Leptin is an adipocyte-secreted hormone that is delivered via a saturable transporter system across the BBB to the brain where it acts on receptors in hypothalamus to control appetite and thermogenesis. Peripheral resistance to leptin due to its impaired brain delivery prevents therapeutic use of leptin in overweight and moderately obese patients. To address this problem, we modify the N-terminal amine of leptin with Pluronic P85 (LepNP85) and administer this conjugate intranasally using the nose-to-brain route to bypass the BBB. We compare this conjugate with the native leptin, the N-terminal leptin conjugate with poly(ethylene glycol) (LepNPEG5K), and two conjugates of leptin with Pluronic P85 attached randomly to the lysine amino groups of the hormone. Our work suggests that selective modification at the N-terminal preserves leptin activity and modification with P85 enhances the nose-to-brain transport of leptin. In conclusion, LepNP85 with optimized conjugation chemistry is a promising candidate for treatment of obesity.
In Chapter III, we demonstrate for the first time that naïve macrophage exosomes interact with intercellular adhesion molecule 1 (ICAM-1) and C-type lectin receptors on brain endothelial cells that form BBB. Upregulation of ICAM-1, a common process in inflammation, promotes macrophage exosomes uptake in the BBB cells. We further demonstrate in vivo that naïve macrophage exosomes, after intravenous (IV) administration, cross the BBB and deliver a cargo protein to the brain parenchyma. The delivery is enhanced in the presence of brain inflammation. Taken together, macrophage exosomes are promising nanocarriers for brain delivery of therapeutic proteins.
Summer 2017
2017
Pharmaceutical sciences
Brain delivery, Exosome, Leptin, Pharmacokinetics, Protein conjugate, Protein delivery
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting institution
Pharmaceutical Sciences
Alexander
Kabanov
Thesis advisor
Shawn
Hingtgen
Thesis advisor
Elena
Batrakova
Thesis advisor
Zhen
Gu
Thesis advisor
William
Banks
Thesis advisor
Alexander Kabanov
Kabanov
Thesis advisor
text
Dongfen
Yuan
Author
Pharmaceutical Sciences Program
Eshelman School of Pharmacy
Delivery of Therapeutic Proteins to the Brain
Protein therapeutics have tremendous potentials to treat disorders in central nervous system (CNS). However, delivery of therapeutic dose of proteins to the brain is challenging due to the blood-brain barrier (BBB). In Chapter I, I summarize the current strategies applied to enhance the brain delivery of therapeutic proteins, including strategies to open the BBB, penetrate the BBB, or bypass the BBB. The advantages and challenges for each technology are described.
In Chapter II, we explore strategies to improve the brain delivery of leptin for treatment of obesity. Leptin is an adipocyte-secreted hormone that is delivered via a saturable transporter system across the BBB to the brain where it acts on receptors in hypothalamus to control appetite and thermogenesis. Peripheral resistance to leptin due to its impaired brain delivery prevents therapeutic use of leptin in overweight and moderately obese patients. To address this problem, we modify the N-terminal amine of leptin with Pluronic P85 (LepNP85) and administer this conjugate intranasally using the nose-to-brain route to bypass the BBB. We compare this conjugate with the native leptin, the N-terminal leptin conjugate with poly(ethylene glycol) (LepNPEG5K), and two conjugates of leptin with Pluronic P85 attached randomly to the lysine amino groups of the hormone. Our work suggests that selective modification at the N-terminal preserves leptin activity and modification with P85 enhances the nose-to-brain transport of leptin. In conclusion, LepNP85 with optimized conjugation chemistry is a promising candidate for treatment of obesity.
In Chapter III, we demonstrate for the first time that naïve macrophage exosomes interact with intercellular adhesion molecule 1 (ICAM-1) and C-type lectin receptors on brain endothelial cells that form BBB. Upregulation of ICAM-1, a common process in inflammation, promotes macrophage exosomes uptake in the BBB cells. We further demonstrate in vivo that naïve macrophage exosomes, after intravenous (IV) administration, cross the BBB and deliver a cargo protein to the brain parenchyma. The delivery is enhanced in the presence of brain inflammation. Taken together, macrophage exosomes are promising nanocarriers for brain delivery of therapeutic proteins.
Summer 2017
2017
Pharmaceutical sciences
Brain delivery, Exosome, Leptin, Pharmacokinetics, Protein conjugate, Protein delivery
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting institution
Pharmaceutical Sciences
Alexander
Kabanov
Thesis advisor
Shawn
Hingtgen
Thesis advisor
Elena
Batrakova
Thesis advisor
Zhen
Gu
Thesis advisor
William
Banks
Thesis advisor
Alexander Kabanov
Kabanov
Thesis advisor
text
Dongfen
Yuan
Creator
Pharmaceutical Sciences Program
Eshelman School of Pharmacy
Delivery of Therapeutic Proteins to the Brain
Protein therapeutics have tremendous potentials to treat disorders in central
nervous system (CNS). However, delivery of therapeutic dose of proteins to the brain is
challenging due to the blood-brain barrier (BBB). In Chapter I, I summarize the current
strategies applied to enhance the brain delivery of therapeutic proteins, including
strategies to open the BBB, penetrate the BBB, or bypass the BBB. The advantages and
challenges for each technology are described. In Chapter II, we explore strategies to
improve the brain delivery of leptin for treatment of obesity. Leptin is an
adipocyte-secreted hormone that is delivered via a saturable transporter system across the
BBB to the brain where it acts on receptors in hypothalamus to control appetite and
thermogenesis. Peripheral resistance to leptin due to its impaired brain delivery prevents
therapeutic use of leptin in overweight and moderately obese patients. To address this
problem, we modify the N-terminal amine of leptin with Pluronic P85 (LepNP85) and
administer this conjugate intranasally using the nose-to-brain route to bypass the BBB. We
compare this conjugate with the native leptin, the N-terminal leptin conjugate with
poly(ethylene glycol) (LepNPEG5K), and two conjugates of leptin with Pluronic P85 attached
randomly to the lysine amino groups of the hormone. Our work suggests that selective
modification at the N-terminal preserves leptin activity and modification with P85
enhances the nose-to-brain transport of leptin. In conclusion, LepNP85 with optimized
conjugation chemistry is a promising candidate for treatment of obesity. In Chapter III,
we demonstrate for the first time that naïve macrophage exosomes interact with
intercellular adhesion molecule 1 (ICAM-1) and C-type lectin receptors on brain
endothelial cells that form BBB. Upregulation of ICAM-1, a common process in inflammation,
promotes macrophage exosomes uptake in the BBB cells. We further demonstrate in vivo that
naïve macrophage exosomes, after intravenous (IV) administration, cross the BBB and
deliver a cargo protein to the brain parenchyma. The delivery is enhanced in the presence
of brain inflammation. Taken together, macrophage exosomes are promising nanocarriers for
brain delivery of therapeutic proteins.
Summer 2017
2017
Pharmaceutical sciences
Brain delivery, Exosome, Leptin, Pharmacokinetics,
Protein conjugate, Protein delivery
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting
institution
Pharmaceutical Sciences
Alexander
Kabanov
Thesis advisor
Shawn
Hingtgen
Thesis advisor
Elena
Batrakova
Thesis advisor
Zhen
Gu
Thesis advisor
William
Banks
Thesis advisor
Alexander Kabanov
Kabanov
Thesis advisor
text
Dongfen
Yuan
Creator
Pharmaceutical Sciences Program
Eshelman School of Pharmacy
Delivery of Therapeutic Proteins to the Brain
Protein therapeutics have tremendous potentials to treat disorders in central nervous system (CNS). However, delivery of therapeutic dose of proteins to the brain is challenging due to the blood-brain barrier (BBB). In Chapter I, I summarize the current strategies applied to enhance the brain delivery of therapeutic proteins, including strategies to open the BBB, penetrate the BBB, or bypass the BBB. The advantages and challenges for each technology are described. In Chapter II, we explore strategies to improve the brain delivery of leptin for treatment of obesity. Leptin is an adipocyte-secreted hormone that is delivered via a saturable transporter system across the BBB to the brain where it acts on receptors in hypothalamus to control appetite and thermogenesis. Peripheral resistance to leptin due to its impaired brain delivery prevents therapeutic use of leptin in overweight and moderately obese patients. To address this problem, we modify the N-terminal amine of leptin with Pluronic P85 (LepNP85) and administer this conjugate intranasally using the nose-to-brain route to bypass the BBB. We compare this conjugate with the native leptin, the N-terminal leptin conjugate with poly(ethylene glycol) (LepNPEG5K), and two conjugates of leptin with Pluronic P85 attached randomly to the lysine amino groups of the hormone. Our work suggests that selective modification at the N-terminal preserves leptin activity and modification with P85 enhances the nose-to-brain transport of leptin. In conclusion, LepNP85 with optimized conjugation chemistry is a promising candidate for treatment of obesity. In Chapter III, we demonstrate for the first time that naïve macrophage exosomes interact with intercellular adhesion molecule 1 (ICAM-1) and C-type lectin receptors on brain endothelial cells that form BBB. Upregulation of ICAM-1, a common process in inflammation, promotes macrophage exosomes uptake in the BBB cells. We further demonstrate in vivo that naïve macrophage exosomes, after intravenous (IV) administration, cross the BBB and deliver a cargo protein to the brain parenchyma. The delivery is enhanced in the presence of brain inflammation. Taken together, macrophage exosomes are promising nanocarriers for brain delivery of therapeutic proteins.
Summer 2017
2017
Pharmaceutical sciences
Brain delivery, Exosome, Leptin, Pharmacokinetics, Protein conjugate, Protein delivery
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting institution
Pharmaceutical Sciences
Alexander
Kabanov
Thesis advisor
Shawn
Hingtgen
Thesis advisor
Elena
Batrakova
Thesis advisor
Zhen
Gu
Thesis advisor
William
Banks
Thesis advisor
Alexander Kabanov
Kabanov
Thesis advisor
text
Dongfen
Yuan
Creator
Division of Pharmacoengineering and Molecular Pharmaceutics
Eshelman School of Pharmacy
Delivery of Therapeutic Proteins to the Brain
Protein therapeutics have tremendous potentials to treat disorders in central nervous system (CNS). However, delivery of therapeutic dose of proteins to the brain is challenging due to the blood-brain barrier (BBB). In Chapter I, I summarize the current strategies applied to enhance the brain delivery of therapeutic proteins, including strategies to open the BBB, penetrate the BBB, or bypass the BBB. The advantages and challenges for each technology are described. In Chapter II, we explore strategies to improve the brain delivery of leptin for treatment of obesity. Leptin is an adipocyte-secreted hormone that is delivered via a saturable transporter system across the BBB to the brain where it acts on receptors in hypothalamus to control appetite and thermogenesis. Peripheral resistance to leptin due to its impaired brain delivery prevents therapeutic use of leptin in overweight and moderately obese patients. To address this problem, we modify the N-terminal amine of leptin with Pluronic P85 (LepNP85) and administer this conjugate intranasally using the nose-to-brain route to bypass the BBB. We compare this conjugate with the native leptin, the N-terminal leptin conjugate with poly(ethylene glycol) (LepNPEG5K), and two conjugates of leptin with Pluronic P85 attached randomly to the lysine amino groups of the hormone. Our work suggests that selective modification at the N-terminal preserves leptin activity and modification with P85 enhances the nose-to-brain transport of leptin. In conclusion, LepNP85 with optimized conjugation chemistry is a promising candidate for treatment of obesity. In Chapter III, we demonstrate for the first time that naïve macrophage exosomes interact with intercellular adhesion molecule 1 (ICAM-1) and C-type lectin receptors on brain endothelial cells that form BBB. Upregulation of ICAM-1, a common process in inflammation, promotes macrophage exosomes uptake in the BBB cells. We further demonstrate in vivo that naïve macrophage exosomes, after intravenous (IV) administration, cross the BBB and deliver a cargo protein to the brain parenchyma. The delivery is enhanced in the presence of brain inflammation. Taken together, macrophage exosomes are promising nanocarriers for brain delivery of therapeutic proteins.
Summer 2017
2017
Pharmaceutical sciences
Brain delivery, Exosome, Leptin, Pharmacokinetics, Protein conjugate, Protein delivery
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting institution
Pharmaceutical Sciences
Alexander
Kabanov
Thesis advisor
Shawn
Hingtgen
Thesis advisor
Elena
Batrakova
Thesis advisor
Zhen
Gu
Thesis advisor
William
Banks
Thesis advisor
Alexander Kabanov
Kabanov
Thesis advisor
text
Dongfen
Yuan
Creator
Division of Pharmacoengineering and Molecular Pharmaceutics
Eshelman School of Pharmacy
Delivery of Therapeutic Proteins to the Brain
Protein therapeutics have tremendous potentials to treat disorders in central nervous system (CNS). However, delivery of therapeutic dose of proteins to the brain is challenging due to the blood-brain barrier (BBB). In Chapter I, I summarize the current strategies applied to enhance the brain delivery of therapeutic proteins, including strategies to open the BBB, penetrate the BBB, or bypass the BBB. The advantages and challenges for each technology are described. In Chapter II, we explore strategies to improve the brain delivery of leptin for treatment of obesity. Leptin is an adipocyte-secreted hormone that is delivered via a saturable transporter system across the BBB to the brain where it acts on receptors in hypothalamus to control appetite and thermogenesis. Peripheral resistance to leptin due to its impaired brain delivery prevents therapeutic use of leptin in overweight and moderately obese patients. To address this problem, we modify the N-terminal amine of leptin with Pluronic P85 (LepNP85) and administer this conjugate intranasally using the nose-to-brain route to bypass the BBB. We compare this conjugate with the native leptin, the N-terminal leptin conjugate with poly(ethylene glycol) (LepNPEG5K), and two conjugates of leptin with Pluronic P85 attached randomly to the lysine amino groups of the hormone. Our work suggests that selective modification at the N-terminal preserves leptin activity and modification with P85 enhances the nose-to-brain transport of leptin. In conclusion, LepNP85 with optimized conjugation chemistry is a promising candidate for treatment of obesity. In Chapter III, we demonstrate for the first time that naïve macrophage exosomes interact with intercellular adhesion molecule 1 (ICAM-1) and C-type lectin receptors on brain endothelial cells that form BBB. Upregulation of ICAM-1, a common process in inflammation, promotes macrophage exosomes uptake in the BBB cells. We further demonstrate in vivo that naïve macrophage exosomes, after intravenous (IV) administration, cross the BBB and deliver a cargo protein to the brain parenchyma. The delivery is enhanced in the presence of brain inflammation. Taken together, macrophage exosomes are promising nanocarriers for brain delivery of therapeutic proteins.
2017-08
2017
Pharmaceutical sciences
Brain delivery, Exosome, Leptin, Pharmacokinetics, Protein conjugate, Protein delivery
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting institution
Pharmaceutical Sciences
Alexander
Kabanov
Thesis advisor
Shawn
Hingtgen
Thesis advisor
Elena
Batrakova
Thesis advisor
Zhen
Gu
Thesis advisor
William
Banks
Thesis advisor
Alexander Kabanov
Kabanov
Thesis advisor
text
Dongfen
Yuan
Creator
Division of Pharmacoengineering and Molecular Pharmaceutics
Eshelman School of Pharmacy
Delivery of Therapeutic Proteins to the Brain
Protein therapeutics have tremendous potentials to treat disorders in central nervous system (CNS). However, delivery of therapeutic dose of proteins to the brain is challenging due to the blood-brain barrier (BBB). In Chapter I, I summarize the current strategies applied to enhance the brain delivery of therapeutic proteins, including strategies to open the BBB, penetrate the BBB, or bypass the BBB. The advantages and challenges for each technology are described. In Chapter II, we explore strategies to improve the brain delivery of leptin for treatment of obesity. Leptin is an adipocyte-secreted hormone that is delivered via a saturable transporter system across the BBB to the brain where it acts on receptors in hypothalamus to control appetite and thermogenesis. Peripheral resistance to leptin due to its impaired brain delivery prevents therapeutic use of leptin in overweight and moderately obese patients. To address this problem, we modify the N-terminal amine of leptin with Pluronic P85 (LepNP85) and administer this conjugate intranasally using the nose-to-brain route to bypass the BBB. We compare this conjugate with the native leptin, the N-terminal leptin conjugate with poly(ethylene glycol) (LepNPEG5K), and two conjugates of leptin with Pluronic P85 attached randomly to the lysine amino groups of the hormone. Our work suggests that selective modification at the N-terminal preserves leptin activity and modification with P85 enhances the nose-to-brain transport of leptin. In conclusion, LepNP85 with optimized conjugation chemistry is a promising candidate for treatment of obesity. In Chapter III, we demonstrate for the first time that naïve macrophage exosomes interact with intercellular adhesion molecule 1 (ICAM-1) and C-type lectin receptors on brain endothelial cells that form BBB. Upregulation of ICAM-1, a common process in inflammation, promotes macrophage exosomes uptake in the BBB cells. We further demonstrate in vivo that naïve macrophage exosomes, after intravenous (IV) administration, cross the BBB and deliver a cargo protein to the brain parenchyma. The delivery is enhanced in the presence of brain inflammation. Taken together, macrophage exosomes are promising nanocarriers for brain delivery of therapeutic proteins.
2017
Pharmaceutical sciences
Brain delivery, Exosome, Leptin, Pharmacokinetics, Protein conjugate, Protein delivery
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting institution
Pharmaceutical Sciences
Alexander
Kabanov
Thesis advisor
Shawn
Hingtgen
Thesis advisor
Elena
Batrakova
Thesis advisor
Zhen
Gu
Thesis advisor
William
Banks
Thesis advisor
Alexander Kabanov
Kabanov
Thesis advisor
text
2017-08
Dongfen
Yuan
Creator
Division of Pharmacoengineering and Molecular Pharmaceutics
Eshelman School of Pharmacy
Delivery of Therapeutic Proteins to the Brain
Protein therapeutics have tremendous potentials to treat disorders in central nervous system (CNS). However, delivery of therapeutic dose of proteins to the brain is challenging due to the blood-brain barrier (BBB). In Chapter I, I summarize the current strategies applied to enhance the brain delivery of therapeutic proteins, including strategies to open the BBB, penetrate the BBB, or bypass the BBB. The advantages and challenges for each technology are described. In Chapter II, we explore strategies to improve the brain delivery of leptin for treatment of obesity. Leptin is an adipocyte-secreted hormone that is delivered via a saturable transporter system across the BBB to the brain where it acts on receptors in hypothalamus to control appetite and thermogenesis. Peripheral resistance to leptin due to its impaired brain delivery prevents therapeutic use of leptin in overweight and moderately obese patients. To address this problem, we modify the N-terminal amine of leptin with Pluronic P85 (LepNP85) and administer this conjugate intranasally using the nose-to-brain route to bypass the BBB. We compare this conjugate with the native leptin, the N-terminal leptin conjugate with poly(ethylene glycol) (LepNPEG5K), and two conjugates of leptin with Pluronic P85 attached randomly to the lysine amino groups of the hormone. Our work suggests that selective modification at the N-terminal preserves leptin activity and modification with P85 enhances the nose-to-brain transport of leptin. In conclusion, LepNP85 with optimized conjugation chemistry is a promising candidate for treatment of obesity. In Chapter III, we demonstrate for the first time that naïve macrophage exosomes interact with intercellular adhesion molecule 1 (ICAM-1) and C-type lectin receptors on brain endothelial cells that form BBB. Upregulation of ICAM-1, a common process in inflammation, promotes macrophage exosomes uptake in the BBB cells. We further demonstrate in vivo that naïve macrophage exosomes, after intravenous (IV) administration, cross the BBB and deliver a cargo protein to the brain parenchyma. The delivery is enhanced in the presence of brain inflammation. Taken together, macrophage exosomes are promising nanocarriers for brain delivery of therapeutic proteins.
2017
Pharmaceutical sciences
Brain delivery, Exosome, Leptin, Pharmacokinetics, Protein conjugate, Protein delivery
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting institution
Pharmaceutical Sciences
Alexander
Kabanov
Thesis advisor
Shawn
Hingtgen
Thesis advisor
Elena
Batrakova
Thesis advisor
Zhen
Gu
Thesis advisor
William
Banks
Thesis advisor
Alexander Kabanov
Kabanov
Thesis advisor
text
2017-08
Dongfen
Yuan
Creator
Division of Pharmacoengineering and Molecular Pharmaceutics
Eshelman School of Pharmacy
Delivery of Therapeutic Proteins to the Brain
Protein therapeutics have tremendous potentials to treat disorders in central nervous system (CNS). However, delivery of therapeutic dose of proteins to the brain is challenging due to the blood-brain barrier (BBB). In Chapter I, I summarize the current strategies applied to enhance the brain delivery of therapeutic proteins, including strategies to open the BBB, penetrate the BBB, or bypass the BBB. The advantages and challenges for each technology are described. In Chapter II, we explore strategies to improve the brain delivery of leptin for treatment of obesity. Leptin is an adipocyte-secreted hormone that is delivered via a saturable transporter system across the BBB to the brain where it acts on receptors in hypothalamus to control appetite and thermogenesis. Peripheral resistance to leptin due to its impaired brain delivery prevents therapeutic use of leptin in overweight and moderately obese patients. To address this problem, we modify the N-terminal amine of leptin with Pluronic P85 (LepNP85) and administer this conjugate intranasally using the nose-to-brain route to bypass the BBB. We compare this conjugate with the native leptin, the N-terminal leptin conjugate with poly(ethylene glycol) (LepNPEG5K), and two conjugates of leptin with Pluronic P85 attached randomly to the lysine amino groups of the hormone. Our work suggests that selective modification at the N-terminal preserves leptin activity and modification with P85 enhances the nose-to-brain transport of leptin. In conclusion, LepNP85 with optimized conjugation chemistry is a promising candidate for treatment of obesity. In Chapter III, we demonstrate for the first time that naïve macrophage exosomes interact with intercellular adhesion molecule 1 (ICAM-1) and C-type lectin receptors on brain endothelial cells that form BBB. Upregulation of ICAM-1, a common process in inflammation, promotes macrophage exosomes uptake in the BBB cells. We further demonstrate in vivo that naïve macrophage exosomes, after intravenous (IV) administration, cross the BBB and deliver a cargo protein to the brain parenchyma. The delivery is enhanced in the presence of brain inflammation. Taken together, macrophage exosomes are promising nanocarriers for brain delivery of therapeutic proteins.
2017
Pharmaceutical sciences
Brain delivery, Exosome, Leptin, Pharmacokinetics, Protein conjugate, Protein delivery
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting institution
Pharmaceutical Sciences
Alexander
Kabanov
Thesis advisor
Shawn
Hingtgen
Thesis advisor
Elena
Batrakova
Thesis advisor
Zhen
Gu
Thesis advisor
William
Banks
Thesis advisor
Alexander Kabanov
Kabanov
Thesis advisor
text
2017-08
Dongfen
Yuan
Creator
Division of Pharmacoengineering and Molecular Pharmaceutics
Eshelman School of Pharmacy
Delivery of Therapeutic Proteins to the Brain
Protein therapeutics have tremendous potentials to treat disorders in central nervous system (CNS). However, delivery of therapeutic dose of proteins to the brain is challenging due to the blood-brain barrier (BBB). In Chapter I, I summarize the current strategies applied to enhance the brain delivery of therapeutic proteins, including strategies to open the BBB, penetrate the BBB, or bypass the BBB. The advantages and challenges for each technology are described. In Chapter II, we explore strategies to improve the brain delivery of leptin for treatment of obesity. Leptin is an adipocyte-secreted hormone that is delivered via a saturable transporter system across the BBB to the brain where it acts on receptors in hypothalamus to control appetite and thermogenesis. Peripheral resistance to leptin due to its impaired brain delivery prevents therapeutic use of leptin in overweight and moderately obese patients. To address this problem, we modify the N-terminal amine of leptin with Pluronic P85 (LepNP85) and administer this conjugate intranasally using the nose-to-brain route to bypass the BBB. We compare this conjugate with the native leptin, the N-terminal leptin conjugate with poly(ethylene glycol) (LepNPEG5K), and two conjugates of leptin with Pluronic P85 attached randomly to the lysine amino groups of the hormone. Our work suggests that selective modification at the N-terminal preserves leptin activity and modification with P85 enhances the nose-to-brain transport of leptin. In conclusion, LepNP85 with optimized conjugation chemistry is a promising candidate for treatment of obesity. In Chapter III, we demonstrate for the first time that naïve macrophage exosomes interact with intercellular adhesion molecule 1 (ICAM-1) and C-type lectin receptors on brain endothelial cells that form BBB. Upregulation of ICAM-1, a common process in inflammation, promotes macrophage exosomes uptake in the BBB cells. We further demonstrate in vivo that naïve macrophage exosomes, after intravenous (IV) administration, cross the BBB and deliver a cargo protein to the brain parenchyma. The delivery is enhanced in the presence of brain inflammation. Taken together, macrophage exosomes are promising nanocarriers for brain delivery of therapeutic proteins.
2017
Pharmaceutical sciences
Brain delivery, Exosome, Leptin, Pharmacokinetics, Protein conjugate, Protein delivery
eng
Doctor of Philosophy
Dissertation
Pharmaceutical Sciences
Alexander
Kabanov
Thesis advisor
Shawn
Hingtgen
Thesis advisor
Elena
Batrakova
Thesis advisor
Zhen
Gu
Thesis advisor
William
Banks
Thesis advisor
Alexander
Kabanov
Thesis advisor
text
2017-08
University of North Carolina at Chapel Hill
Degree granting institution
Dongfen
Yuan
Creator
Division of Pharmacoengineering and Molecular Pharmaceutics
Eshelman School of Pharmacy
Delivery of Therapeutic Proteins to the Brain
Protein therapeutics have tremendous potentials to treat disorders in central nervous system (CNS). However, delivery of therapeutic dose of proteins to the brain is challenging due to the blood-brain barrier (BBB). In Chapter I, I summarize the current strategies applied to enhance the brain delivery of therapeutic proteins, including strategies to open the BBB, penetrate the BBB, or bypass the BBB. The advantages and challenges for each technology are described. In Chapter II, we explore strategies to improve the brain delivery of leptin for treatment of obesity. Leptin is an adipocyte-secreted hormone that is delivered via a saturable transporter system across the BBB to the brain where it acts on receptors in hypothalamus to control appetite and thermogenesis. Peripheral resistance to leptin due to its impaired brain delivery prevents therapeutic use of leptin in overweight and moderately obese patients. To address this problem, we modify the N-terminal amine of leptin with Pluronic P85 (LepNP85) and administer this conjugate intranasally using the nose-to-brain route to bypass the BBB. We compare this conjugate with the native leptin, the N-terminal leptin conjugate with poly(ethylene glycol) (LepNPEG5K), and two conjugates of leptin with Pluronic P85 attached randomly to the lysine amino groups of the hormone. Our work suggests that selective modification at the N-terminal preserves leptin activity and modification with P85 enhances the nose-to-brain transport of leptin. In conclusion, LepNP85 with optimized conjugation chemistry is a promising candidate for treatment of obesity. In Chapter III, we demonstrate for the first time that naïve macrophage exosomes interact with intercellular adhesion molecule 1 (ICAM-1) and C-type lectin receptors on brain endothelial cells that form BBB. Upregulation of ICAM-1, a common process in inflammation, promotes macrophage exosomes uptake in the BBB cells. We further demonstrate in vivo that naïve macrophage exosomes, after intravenous (IV) administration, cross the BBB and deliver a cargo protein to the brain parenchyma. The delivery is enhanced in the presence of brain inflammation. Taken together, macrophage exosomes are promising nanocarriers for brain delivery of therapeutic proteins.
2017
Pharmaceutical sciences
Brain delivery; Exosome; Leptin; Pharmacokinetics; Protein conjugate; Protein delivery
eng
Doctor of Philosophy
Dissertation
Pharmaceutical Sciences
Alexander
Kabanov
Thesis advisor
Shawn
Hingtgen
Thesis advisor
Elena
Batrakova
Thesis advisor
Zhen
Gu
Thesis advisor
William
Banks
Thesis advisor
Alexander
Kabanov
Thesis advisor
text
2017-08
University of North Carolina at Chapel Hill
Degree granting institution
Dongfen
Yuan
Creator
Division of Pharmacoengineering and Molecular Pharmaceutics
Eshelman School of Pharmacy
Delivery of Therapeutic Proteins to the Brain
Protein therapeutics have tremendous potentials to treat disorders in central nervous system (CNS). However, delivery of therapeutic dose of proteins to the brain is challenging due to the blood-brain barrier (BBB). In Chapter I, I summarize the current strategies applied to enhance the brain delivery of therapeutic proteins, including strategies to open the BBB, penetrate the BBB, or bypass the BBB. The advantages and challenges for each technology are described. In Chapter II, we explore strategies to improve the brain delivery of leptin for treatment of obesity. Leptin is an adipocyte-secreted hormone that is delivered via a saturable transporter system across the BBB to the brain where it acts on receptors in hypothalamus to control appetite and thermogenesis. Peripheral resistance to leptin due to its impaired brain delivery prevents therapeutic use of leptin in overweight and moderately obese patients. To address this problem, we modify the N-terminal amine of leptin with Pluronic P85 (LepNP85) and administer this conjugate intranasally using the nose-to-brain route to bypass the BBB. We compare this conjugate with the native leptin, the N-terminal leptin conjugate with poly(ethylene glycol) (LepNPEG5K), and two conjugates of leptin with Pluronic P85 attached randomly to the lysine amino groups of the hormone. Our work suggests that selective modification at the N-terminal preserves leptin activity and modification with P85 enhances the nose-to-brain transport of leptin. In conclusion, LepNP85 with optimized conjugation chemistry is a promising candidate for treatment of obesity. In Chapter III, we demonstrate for the first time that naïve macrophage exosomes interact with intercellular adhesion molecule 1 (ICAM-1) and C-type lectin receptors on brain endothelial cells that form BBB. Upregulation of ICAM-1, a common process in inflammation, promotes macrophage exosomes uptake in the BBB cells. We further demonstrate in vivo that naïve macrophage exosomes, after intravenous (IV) administration, cross the BBB and deliver a cargo protein to the brain parenchyma. The delivery is enhanced in the presence of brain inflammation. Taken together, macrophage exosomes are promising nanocarriers for brain delivery of therapeutic proteins.
2017
Pharmaceutical sciences
Brain delivery, Exosome, Leptin, Pharmacokinetics, Protein conjugate, Protein delivery
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting institution
Pharmaceutical Sciences
Alexander
Kabanov
Thesis advisor
Shawn
Hingtgen
Thesis advisor
Elena
Batrakova
Thesis advisor
Zhen
Gu
Thesis advisor
William
Banks
Thesis advisor
Alexander
Kabanov
Thesis advisor
text
2017-08
Dongfen
Yuan
Creator
Division of Pharmacoengineering and Molecular Pharmaceutics
Eshelman School of Pharmacy
Delivery of Therapeutic Proteins to the Brain
Protein therapeutics have tremendous potentials to treat disorders in central nervous system (CNS). However, delivery of therapeutic dose of proteins to the brain is challenging due to the blood-brain barrier (BBB). In Chapter I, I summarize the current strategies applied to enhance the brain delivery of therapeutic proteins, including strategies to open the BBB, penetrate the BBB, or bypass the BBB. The advantages and challenges for each technology are described. In Chapter II, we explore strategies to improve the brain delivery of leptin for treatment of obesity. Leptin is an adipocyte-secreted hormone that is delivered via a saturable transporter system across the BBB to the brain where it acts on receptors in hypothalamus to control appetite and thermogenesis. Peripheral resistance to leptin due to its impaired brain delivery prevents therapeutic use of leptin in overweight and moderately obese patients. To address this problem, we modify the N-terminal amine of leptin with Pluronic P85 (LepNP85) and administer this conjugate intranasally using the nose-to-brain route to bypass the BBB. We compare this conjugate with the native leptin, the N-terminal leptin conjugate with poly(ethylene glycol) (LepNPEG5K), and two conjugates of leptin with Pluronic P85 attached randomly to the lysine amino groups of the hormone. Our work suggests that selective modification at the N-terminal preserves leptin activity and modification with P85 enhances the nose-to-brain transport of leptin. In conclusion, LepNP85 with optimized conjugation chemistry is a promising candidate for treatment of obesity. In Chapter III, we demonstrate for the first time that naïve macrophage exosomes interact with intercellular adhesion molecule 1 (ICAM-1) and C-type lectin receptors on brain endothelial cells that form BBB. Upregulation of ICAM-1, a common process in inflammation, promotes macrophage exosomes uptake in the BBB cells. We further demonstrate in vivo that naïve macrophage exosomes, after intravenous (IV) administration, cross the BBB and deliver a cargo protein to the brain parenchyma. The delivery is enhanced in the presence of brain inflammation. Taken together, macrophage exosomes are promising nanocarriers for brain delivery of therapeutic proteins.
2017
Pharmaceutical sciences
Brain delivery; Exosome; Leptin; Pharmacokinetics; Protein conjugate; Protein delivery
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting institution
Alexander
Kabanov
Thesis advisor
Shawn
Hingtgen
Thesis advisor
Elena
Batrakova
Thesis advisor
Zhen
Gu
Thesis advisor
William
Banks
Thesis advisor
Alexander
Kabanov
Thesis advisor
text
2017-08
Yuan_unc_0153D_17230.pdf
uuid:58a1e10f-aafb-43ca-89ea-0bb42880dcb1
proquest
2019-08-15T00:00:00
2017-07-22T03:24:00Z
application/pdf
10671417
yes